C Hooper1, P De Souto Barreto, N Coley, C Cantet, M Cesari, S Andrieu, B Vellas. 1. Claudie Hooper, Gérontopôle, Department of Geriatrics, CHU Toulouse, Purpan University Hospital, Toulouse, France: claudie28@yahoo.com, Tel : +33 (5) 61 77 64 25, Fax : +33 (5) 61 77 64 75.
Abstract
OBJECTIVES: To investigate the changes in specific domains of cognitive function in older adults reporting subjective memory complaints with a low omega-3 index receiving omega 3polyunsaturated fatty acid (n-3 PUFA) supplementation or placebo. DESIGN: This is a secondary exploratory analysis of the Multidomain Alzheimer Preventive Trial (MAPT) using subjects randomized to the n-3 PUFA supplementation or placebo group. SETTING:French community dwellers aged 70 or over reporting subjective memory complaints, but free from clinical dementia. PARTICIPANTS: A subgroup of MAPT subjects in the lowest quartile of omega-3 index distribution with baseline values ≤ 4.83 % (n = 183). INTERVENTION: The n-3 PUFA supplementation group consumed a daily dose of DHA (800 mg) and EPA (a maximum amount of 225 mg) for 3 years. The placebo group received identical capsules comprising liquid paraffin oil. MEASUREMENTS: Linear mixed-model repeated-measures analyses were used including baseline, 6, 12, 24 and 36-month follow-up data to assess between-group differences in the change in eight cognitive tests over 36 months. RESULTS: There was less decline on the Controlled Oral Word Association Test (COWAT) in the n-3 PUFA supplementation group compared to placebo (p = 0.009; between group mean difference over 36 months, 2.3; 95% CI, 0.6,4.0). No significant differences for any of the other cognitive tests were found, including other tests of executive functioning, although, numerically all results were in favour of the n-3 PUFA supplementation. CONCLUSIONS: We found some evidence that n-3 PUFAs might be beneficial for the maintenance of executive functioning in older adults at risk of dementia with low omega-3 index, but this exploratory finding requires further confirmation. A larger specifically designed randomised controlled trial could be merited.
RCT Entities:
OBJECTIVES: To investigate the changes in specific domains of cognitive function in older adults reporting subjective memory complaints with a low omega-3 index receiving omega 3 polyunsaturated fatty acid (n-3 PUFA) supplementation or placebo. DESIGN: This is a secondary exploratory analysis of the Multidomain Alzheimer Preventive Trial (MAPT) using subjects randomized to the n-3 PUFA supplementation or placebo group. SETTING: French community dwellers aged 70 or over reporting subjective memory complaints, but free from clinical dementia. PARTICIPANTS: A subgroup of MAPT subjects in the lowest quartile of omega-3 index distribution with baseline values ≤ 4.83 % (n = 183). INTERVENTION: The n-3 PUFA supplementation group consumed a daily dose of DHA (800 mg) and EPA (a maximum amount of 225 mg) for 3 years. The placebo group received identical capsules comprising liquid paraffin oil. MEASUREMENTS: Linear mixed-model repeated-measures analyses were used including baseline, 6, 12, 24 and 36-month follow-up data to assess between-group differences in the change in eight cognitive tests over 36 months. RESULTS: There was less decline on the Controlled Oral Word Association Test (COWAT) in the n-3 PUFA supplementation group compared to placebo (p = 0.009; between group mean difference over 36 months, 2.3; 95% CI, 0.6,4.0). No significant differences for any of the other cognitive tests were found, including other tests of executive functioning, although, numerically all results were in favour of the n-3 PUFA supplementation. CONCLUSIONS: We found some evidence that n-3 PUFAs might be beneficial for the maintenance of executive functioning in older adults at risk of dementia with low omega-3 index, but this exploratory finding requires further confirmation. A larger specifically designed randomised controlled trial could be merited.
Authors: Philippe Legrand; B Schmitt; J Mourot; D Catheline; G Chesneau; M Mireaux; N Kerhoas; P Weill Journal: Lipids Date: 2009-12-11 Impact factor: 1.880
Authors: O van de Rest; J M Geleijnse; F J Kok; W A van Staveren; C Dullemeijer; M G M Olderikkert; A T F Beekman; C P G M de Groot Journal: Neurology Date: 2008-08-05 Impact factor: 9.910
Authors: Serge Gauthier; P S Aisen; J Cummings; M J Detke; F M Longo; R Raman; M Sabbagh; L Schneider; R Tanzi; P Tariot; M Weiner; J Touchon; B Vellas Journal: J Prev Alzheimers Dis Date: 2020-04-06
Authors: Marialaura Simonetto; Marco Infante; Ralph L Sacco; Tatjana Rundek; David Della-Morte Journal: Nutrients Date: 2019-09-23 Impact factor: 5.717
Authors: Markus S Anker; Stefan D Anker; Andrew J S Coats; Stephan von Haehling Journal: J Cachexia Sarcopenia Muscle Date: 2019-12 Impact factor: 12.910